0001062993-22-013521.txt : 20220525
0001062993-22-013521.hdr.sgml : 20220525
20220525181813
ACCESSION NUMBER: 0001062993-22-013521
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220523
FILED AS OF DATE: 20220525
DATE AS OF CHANGE: 20220525
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gillheeney Gary S.
CENTRAL INDEX KEY: 0001757373
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37906
FILM NUMBER: 22964405
MAIL ADDRESS:
STREET 1: C/O ORGANOGENESIS INC.
STREET 2: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Organogenesis Holdings Inc.
CENTRAL INDEX KEY: 0001661181
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
BUSINESS PHONE: 781-575-0775
MAIL ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
FORMER COMPANY:
FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp.
DATE OF NAME CHANGE: 20151215
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2022-05-23
0001661181
Organogenesis Holdings Inc.
ORGO
0001757373
Gillheeney Gary S.
C/O ORGANOGENESIS HOLDINGS INC.
85 DAN ROAD
CANTON
MA
02021
1
1
0
0
President and CEO
Class A Common Stock
2022-05-23
4
M
0
6670
0.99
A
404912
D
Class A Common Stock
2022-05-23
4
M
0
53680
0.99
A
458592
D
Class A Common Stock
2022-05-23
4
S
0
6670
5.84
D
451922
D
Class A Common Stock
2022-05-23
4
S
0
53680
5.80
D
398242
D
Class A Common Stock
2022-05-24
4
M
0
52312
0.99
A
450554
D
Class A Common Stock
2022-05-24
4
S
0
52312
5.66
D
398242
D
Class A Common Stock
2022-05-25
4
M
0
84674
0.99
A
482916
D
Class A Common Stock
2022-05-25
4
S
0
84674
5.60
D
398242
D
Stock Option (Right to Buy)
0.99
2022-05-23
4
M
0
6670
0
D
2024-12-08
Class A Common Stock
6670
1067245
D
Stock Option (Right to Buy)
0.99
2022-05-23
4
M
0
53680
0
D
2024-08-21
Class A Common Stock
53680
611124
D
Stock Option (Right to Buy)
0.99
2022-05-24
4
M
0
52312
0
D
2024-08-21
Class A Common Stock
52312
558812
D
Stock Option (Right to Buy)
0.99
2022-05-25
4
M
0
84674
0
D
2024-08-21
Class A Common Stock
84674
474138
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $6.05, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.705 to $5.93, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.60 to $5.73, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.47 to $5.72, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
100% of the shares subject to the option are fully vested and exercisable.
/s/ William R. Kolb, Attorney-in-Fact
2022-05-25